Live Webinar | June 23 | 7 pm ET
The Access Inflection: When the 2025 Playbook Stops Working
5 real-time signals on how U.S. market access
is restructuring in 2026
Market access teams are entering 2026 with more pressure, more complexity, and less room for outdated assumptions.
Join eMAX Health for a live webinar built from recent insights gathered through MAVA®, eMAX Health’s real-time stakeholder insight platform. Christian Bennett and an expert access payer panel will explore what recent payer, provider, and IDN perspectives reveal about the next access playbook.
DATE: June 23, 2026
TIME: 7 pm ET
FORMAT: Live Webinar
MODERATOR: Christian Bennett
FEATURING: Expert panel of payer and access decision-makers
The access landscape is shifting faster than traditional planning cycles.
Pricing pressure, biosimilar competition, formulary narrowing, utilization management, evidence expectations, and pull-through barriers are changing how pharma and biotech teams need to plan for launch and lifecycle strategy.
This webinar will examine five real-time signals emerging from recent MAVA® insights and discuss what those signals mean for teams making decisions around pricing, contracting, evidence, coverage, and pull-through execution.
Five signals reshaping the 2026 access playbook
Pricing in the Post-MFN World
How payer behavior is shifting in response to global pricing pressure.
The Biosimilar Cliff Cascade
Why generic and biosimilar launches can rapidly reset class economics.
The Quiet Crackdown
How crowded classes are facing narrowing, step therapy, and more aggressive UM.
The Pull-Through Trap
Why approval does not always translate into access.
Rare Disease
as a
Leading Indicator
How rare disease may foreshadow broader changes in stakeholder engagement, evidence, and reimbursement models.
A live discussion built for practical insight
Christian Bennett will lead a live expert panel through three key questions for each signal:
-
What is the data actually saying?
-
What does it mean for pharma?
-
What should teams do differently now?
The goal is to move beyond broad trends and into practical implications for market access, pricing, contracting, HEOR, commercial strategy, and launch planning teams.
Designed for pharma and biotech teams focused on access strategy
This session is especially relevant for teams involved in:
-
Market access strategy
-
Pricing and contracting
-
Payer marketing
-
HEOR and evidence planning
-
Launch readiness
-
Reimbursement
-
Pull-through execution
-
Value strategy
-
Oncology
-
Rare disease
-
Immunology
-
Specialty markets
Powered by MAVA® real-time stakeholder insight
MAVA® is eMAX Health’s real-time stakeholder insight platform, helping pharmaceutical and biotech teams pressure-test access strategy with structured input from payer, provider, patient, and channel intermediary stakeholders.
This webinar draws on recent MAVA® insights from payer, provider, and IDN perspectives to explore how access decision-making is evolving in 2026.
Christian Bennett | Sr. Vice President, Market Access
Global market access • Pricing and reimbursement • Contracting strategy • Launch planning • Value development
Chris brings more than 25 years of healthcare consulting experience supporting pharmaceutical and biotechnology clients across U.S. and international market access strategy. His work spans global value development, pricing, reimbursement, contracting, and launch strategy across therapeutic areas including oncology, immunology, dermatology, CNS, endocrinology, cardiovascular, and rare/orphan diseases. Before joining eMAX Health, Chris served as Managing Director at a global consultancy, where he led a team of more than 100 market access professionals delivering high-impact access solutions.
Presenter
Are your 2026 access strategies built for the market that is emerging?
Join eMAX Health for a live expert discussion on the real-time signals reshaping market access strategy.
